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Enhancement of bioreductive drug toxicity in murine
tumours by inhibition of the activity of nitric oxide
synthase
SA Butler, PJ Wood, S Cole, C Williams, GE Adams and IJ Stratford
Medical Research Council, Harwell, Oxon OX11 ORD, UK
Summary Nitro-L-arginine inhibits the production of nitric oxide and can thereby cause vasoconstriction in vivo. One consequence of this is
that nitro-L-arginine can increase hypoxia in a range of transplantable and spontaneous murine solid tumours. Bioreductive drugs such as
RB6145 are more active under hypoxic conditions, and the combination of RB6145 with nitro-L-arginine in vivo shows greater anti-tumour
activity than either agent individually. In mice given nitro-L-arginine at 10 mg kg-' i.p. up to 1 h before orafter 300 mg kg-' i.p. RB6145, survival
of KHT tumour cells was reduced by 3-4 logs when assessed by clonogenic assay 24 h after treatment. RB6145 or nitro-L-arginine alone
caused no more than 20% cell kill. Similar effects were found in SCCVII tumours. The tumour response to the drug combination was tumour
size dependent, with increased tumour cell sensitivity occurring when the tumour volume at the time of treatment was increased. Further, the
response of KHT tumours to the combination of RB6145 and nitro-L-arginine was also dependent on the time interval between treatment and
on when tumours were excised for determination of survival in vitro. The relative surviving fraction was about 0.3 for intervals less than 4 h but
was reduced to 0.01 at 12 h and 0.001 at 24 h. These results were supported by histological examination of tumours, when necrosis at 2 h
after treatment was less than 5% but increased to greater than 90% at 24 h. RB6145-induced normal tissue damage, as measured by CFU-
A survival, was not altered bycombining with nitro-L-arginine. Hence, this drug combination may provide therapeutic benefit. It is likely that the
substantial anti-tumour effects are due to enhancement of bioreductive toxicity through increased tumour hypoxia, although additional
mechanism(s) may also contribute to the overall response.
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Nitric oxide (NO) is a messenger molecule in a range of normal
cells and tissues. One site of NO activity is the vascular endothe-
lium where it acts as a vasodilator and is responsible, in part, for
maintaining cardiovascular homeostasis (Moncada et al, 1991).
NO is synthesized from L-arginine by the enzyme NO synthase
(NOS). It has recently been shown that elevated levels ofNOS are
present in human tumours compared with surrounding normal
tissue and further that the expression of NOS is related to tumour
grade (Thomsen et al, 1994, 1995; Cobbs et al, 1995; Rosbe et al,
1995). Inhibition of NOS activity has been shown to decrease
blood flow in an experimental mouse tumour model (Andrade et
al, 1992). Thus, it was suggested that should reduced tumourblood
flow, brought about by inhibition of NOS activity, result in a
reduction of tumour oxygenation, then this could provide a novel
approach for enhancing the efficiency of hypoxia-mediated bio-
reductive drug treatment ofcancer (Wood et al, 1993, 1994a).
Using non-invasive 31 magnetic resonance spectroscopy, it has
been shown that administration of the NOS inhibitor nitro-L-argi-
nine to mice can increase the ratio of inorganic phosphate (Pi) to
high-energy phosphates (NTP) in transplantable and spontaneous
tumours (Wood et al, 1993, 1994a and b). These changes were
consistent with an increase in the level of hypoxia in these
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tumours, and this interpretation was confirmed when it was
demonstrated that nitro-L-arginine increased the resistance of
tumours to radiation (Wood et al, 1993, 1994a).
There have been many reports showing that vasoactive agents
can reduce blood flow in experimental and human tumours
(Chaplin and Trotter, 1991). Such reductions can lower the oxygen
status of tumours and thereby cause radiation resistance (Kruuv et
al, 1967; Stratford et al, 1989). This so-called 'stealing effect' has
been exploited to increase the anti-tumour efficiency of various
bioreductive drugs (Chaplin, 1986, 1989). One of the largest
enhancements was obtained by combining hydralazine with
RSU1069 (Chaplin and Acker, 1987). More recently, a prodrug of
RSU1069 has been prepared and licensed to the pharmaceutical
industry for clinical development. This drug, RB6145 (Jenkins et
al, 1990), has also been shown to have considerable anti-tumour
activity when combined with treatments that increase the level of
tumour hypoxia (Bremner 1993; Stratford et al, 1994). Thus, in
view of the findings on induction of hypoxia in murine tumours
after the inhibition of NOS activity, experiments were carried out
in which RB6145 was combined with nitro-L-arginine (Wood et al,
1994a). In the KHT tumour, the drug combination produced a
profound anti-tumour effect. A dose of each agent, which alone
produced no more than 20% tumour cell kill, when combined,
resulted in a surviving fraction less than 103. The aim of the
present work has been to further characterize the anti-tumourprop-
erties of RB6145 combined with nitro-L-arginine, to assess likely
therapeutic benefit and to gain some insight into the underlying
mechanism by which this drug combination becomes so effective.
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MATERIALS AND METHODS
Mice and tumours
C3H/He mice were obtained from NIMR, Mill Hill, UK, in 1984
and subsequently bred in isolators at the MRC Radiobiology Unit
to provide UK-specified pathogen-free category IV animals. Male
and female 8- to 12-week-old mice were used for experiments,
which were carried out under the guidance issued by the MRC in
'Responsibility in the use of animals for medical research (July
1993)' and Home Office project licence no. 30/00835.
The transplantable KHT sarcoma and SCCVIIIHa carcinoma
were used in this study. The KHT was maintained by intramuscular
inoculation of a tumour brei for up to 12 consecutive passages and
then re-established from frozen stocks. The SCCVII/Ha was main-
tained according to the method of Twentyman et al (1980). For
experimentation, 2 x 105 viable tumour cells obtained by trypsin/
DNAase digestion were injected intradermally under sterile condi-
tions in the mid-dorsal pelvic regions ofthe mice. Treatments were
initiated 10-17 days later when tumour volumes were between
100 and 500 mm3.
Drugs
RB6145 (1-[3-(2-bromoethylamino)-2-hydroxypropyl]-2-nitroim-
idazole) was synthesized at the MRC Unit, Harwell, UK. RB6145
has a chiral centre and CIIOIO is the R-isomer; this was supplied
by Warner-Lambert/Parke-Davis, Ann Arbor, MI, USA (Naylor et
al, 1993). Solutions ofthese agents were prepared in acetate buffer
(pH 5.3) no more than 10 min before use. Samples were protected
from light and administered to mice by the intraperitoneal route
(i.p.) in a volume of0.02 ml per g of mouse body weight. Nitro-L-
arginine was injected i.p. at a volume of 0.01 ml per g of mouse
body weight.
Irradiation
A Pantac X-ray set was used to produce 240-kV X-rays (14 mA) at
a dose rate of 3.8 Gy min-', with filtration giving a HVL equiva-
lent to 1.3-mm Cu. Doses were monitored with an air chamber
corrected for ambient temperature and pressure. Unanaesthetized
mice were restrained in polyvinyl jigs with lead shielding and a
cut-away section to allow local irradiation of the tumour by the
unilateral beam (Sheldon and Hill, 1977). Up to four mice in jigs
were mounted onto a collimator plate on the head ofthe X-ray set,
and jigs were turned through 1800 halfway through the exposure
time to provide dose homogeneity.
Survival of tumour cells
Tumours were assayed for survival 2-24 h after treatment, using
an in vivo/in vitro clonogenic assay. Tumours were excised,
weighed, minced with scissors and then digested to a single-cell
suspension for 30 min at 37°C in 0.5 ml of5% trypsin (1:250) and
DNAase, 1.25 mg per 10 ml of phosphate-buffered saline (PBS)
for KHT and in 6 mg of Pronase-2 mg DNAase-2 mg collagenase
per 10 ml ofPBS for SCCVII/Ha. Cell suspensions were pelleted,
washed and resuspended, counted using a haemocytometer and
then diluted before plating. KHT cells were plated in Ham's F-12
medium with 20% newborn calf serum and antibiotics, using a
soft-agar method (Thompson and Rauth, 1974). SCCVII/Ha cells
were plated in RPMI 1640 with 15% fetal calf serum, glutamine
and antibiotics. Plates were incubated for 12-14 days at 37°C in
5% carbon dioxide, 5% oxygen in nitrogen. KHT colonies were
scored under low-power magnification. SCCVIIIHa colonies were
fixed, stained with methylene blue and then scored by eye.
Surviving fraction was calculated as the number of colonies
counted divided by the number of cells plated for a given treat-
ment multiplied by the same fraction determined for untreated
control tumours (plating efficiency). Plating efficiency ranged
between 0.44 and 0.86 (mean 0.59) and 0.17 and 0.73 (mean 0.46)
for the KHT and SCCVII/Ha tumours respectively. The yield of
cells (per g) from untreated tumours averaged (1.21 ± 1.29) x 108,
n = 30 (KHT) and (3.36 ± 2.29) x 101, n = 13 (SCCVII). For treat-
ments that resulted in a reduced cell yield during the digestion of
the tumour, a relative surviving fraction was used. This was calcu-
lated as above, but the number ofcolonies counted divided by the
number of cells plated for both control and treated tumours were
multiplied by the cell yield corrected for the weight of each
tumour.
Tumour growth delay
Mice, 6-10 per group, were treated when tumours reached a
volume of 100-200 mm3 (calculated from the product of three
orthogonal diameters multiplied by i/6). After treatment, the
tumours were measured three times weekly. The end point was the
time taken to reach four times the tumour volume at the time of
treatment.
Histological assessment of tumour toxicity
Mice were treated with RB6145, nitro-L-arginine or a combination
of the two drugs; tumours were excised 2-24 hours later, fixed in
formal saline, embedded in wax, sectioned and stained with
haematoxylin and eosin (H and E). Per cent necrosis was estimated
by eye, by an independent pathologist (Dr L Cobb) viewing coded
slides. These were derived from cross-sections taken through the
centre of each tumour. Assessment of necrosis was made by
viewing the whole area ofthe tumour, and necrosis was defined as
regions of tumour containing all debris and cells in which chro-
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Figure 1 Relative survival of cells from KHT tumours in mice treated with
various doses ofC01010 followed 15 min later by 10 mg kg-' nitro-L-arginine.
Tumours were excised for clonogenic assay 24 h after treatment. Individual
tumours (3-6) were used to derive each point, which are expressed as mean
values ± s.e.
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Figure 2 Relative survival of cells from tumours in mice treated with
10 mg kg-1 nitro-L-arginine at various times before (-) or after (+) 300 mg kg-1
RB6145. Tumours were excised for clonogenic assay 24 h after the first
treatment. (A) KHT tumours. Up to nine individual tumours were used to
derive each point, with the exception of the +15 min point for which all
data from 58 tumours were used. Data are expressed as means ± s.e.
Size range at time of treatment was 50-520 mm3. (B) SCCVII/Ha tumours.
Individual tumours (5-14) were used to derive each point, which are
expressed in mean values ± s.e. Size range at time of treatment was
520-200 mm3
matin had condensed in such a way that normal nuclear structure
was ablated. In addition, eosin staining ofthe cytoplasm was often
stronger in these necrotic cells.
Clonogenic assays of bone marrow stem cells
Bone marrow was flushed from the femurs ofgroups ofthree mice
24 h after treatment oftumour-bearing mice with RB6145, nitro-L-
arginine or a combination of the two drugs. Haemopoietic stem
cells, measured as CFU-A (Pluznik and Sachs 1965), were assayed
by plating 104 cells in 4.5-cm Petri dishes containing 0.3% agar in
2 ml ofalpha-modified minimal essential medium (MEM) supple-
mented with horse serum, antibiotics and glutamine. Media
conditioned by the cell lines L929 and AFi.19T provided the
colony-stimulating activities (Austin et al, 1971). Triplicate
cultures were incubated at 37°C in a humidified atmosphere of
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Figure 3 Effect of tumour size at the time of treatment on relative survival of
cells from KHT tumours in mice treated with 300 mg kg-' RB6145 followed
15 min later by 10 mg kg-1 nitro-L-arginine. Tumours were excised for
clonogenic assay 24 h after treatment. Individual tumours (2-18) were used
to derive each point, which are expressed as mean values ± s.e
10% carbon dioxide, 5% oxygen and 85% nitrogen for 11 days.
Colonies greater than 2 mm in diameter were counted.
RESULTS
Ithas been shown previously thatgiving mice 300 mg kg-' RB6145
followed 15 min later by nitro-L-arginine can reduce survival of
KHT tumour cells to less than 10-3 (Wood et al, 1994a). Figure 1
shows that a similar large amount of cell killing can be obtained
with CIIOIO, a resolved stereo-isomer of RB6145 that is being
taken forward forclinical development. In these experiments, doses
ofCII010ranging from 50-300mg kg-' were given to mice 15 min
before treatment with 10mgkg-' nitro-L-arginine. These drug doses
alone killed no more than 20% of tumour cells. The timing of the
drug administrations was on the basis that 15 min should be long
enough for CIIOlO, and/or the active species derived from it, to
reach a high tumour concentration (Binger and Workman 1990;
Cole et al, 1991) before hypoxia is induced by treatment with nitro-
L-arginine. This sequence has previously been found to be optimal
for the use of RSU1069 with other methods of inducing tumour
hypoxia (Bremner et al, 1990; Bremner, 1993).
To furtherevaluate the interaction between RB6145 and nitro-L-
arginine the interval between the administration of the drugs was
varied. Data for the KHT tumour are given in Figure 2A. The most
potent effect was obtained when the drugs were given within 1 h of
each other. However, significant toxicity was still observed when
the nitro-L-arginine was given 2-4 h before or after the RB6145.
Similar experiments were performed using the SCCVII/Ha carci-
noma (Figure 2B). Anti-tumour effects appeared to be maximal, in
general, when the drugs were given within 15 min of each other,
but this was not as large as could be achieved in the KHT tumour.
Further, if the nitro-L-arginine was given 1 or 2 h after the
RB6145, no synergistic interaction was observed.
Inspection ofthe errorbars in Figure 2 indicate substantial inter-
mouse variation when measuring the response of tumours to the
drug combination. One reason for this is the strong dependency on
tumour size forthe magnitude ofcell killing obtained. This is illus-
trated in Figure 3, which shows that larger KHT tumours are more
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JLTable 1 Changes in the extent of necrosis in KHT tumours at various times
after treatment with 300 mg kg-' RB6145 followed 15 min later by 10 mg kg-'
nitro-L-arginine
Time of excision Necrosis (%)
after treatment (h)
2 < 5, < 5, < 5, < 5, < 5
4 < 5, < 5, 25-50, 5-10, 10-25, < 5
12 40-60, 40-60, 60-70, 60-70, 80-90, 50-60
24 95, 95, 95, 95, -70, -80, -80
sensitive than small tumours to treatment with RB6145, followed
15 min later by nitro-L-arginine.
Small KHT tumours (100-150 mm3) were assayed for response
to RB6145 and nitro-L-arginine using growth delay as the end
point. These tumours when untreated took 3.1 ± 0.25 days to reach
four times their initial volume, and a similar result was obtained
when mice were given nitro-L-arginine alone (3.4 ± 0.61 days). In
this experiment, RB6145 alone had a small effect on tumour
growth (4.7 ± 0.15 days); however, for 300 mg kg-' RB6145
followed 15 min laterby 10 mg kg-' nitro-L-arginine, the time taken
to reach four times the volume at treatment was 9.2 ± 0.92 days.
Groups ofmice with KHT tumours (200-300mm3) were treated
with 300 mg kg-1 RB6145 followed 15 min later by 10 mg kg-'
nitro-L-arginine, and the tumours were excised at various times
thereafter for histological evaluation. Table 1 lists the assessment
of the percentage necrosis present in each of these tumours. In
untreated KHT tumours or in KHT tumours treated with RB6145
or nitro-L-arginine alone, the percentage necrosis at 24 h is usually
about 5% (data not shown). However, in tumours in mice treated
with this drug combination, there is a progressive increase in
necrosis as a function ofthe time after treatment. This is illustrated
in Figure 4, which compares an H and E stained section of an
untreated KHT tumour with that from a mouse treated 24 h previ-
ously with RB6145 and nitro-L-arginine. Figure 4A shows a cross-
section from a 200-mm3 untreated tumour. This section indicates a
highly cellular, apparently well vascularized, undifferentiated
tumour with little obvious structure and little or no necrosis. In
contrast, Figure 4B, a section from a similar-sized drug-treated
tumour, shows large numbers of pycnotic cells, which may be a
consequence ofhaemorrhagic necrosis. There is little evidence of
viable tumour tissue in this section.
To appreciate what this change in percentage necrosis may mean
in relation to survival of cells from KHT tumours, parallel clono-
genic assays were carried out as a function of time after treatment
with RB6145 and nitro-L-arginine. Figure 5 shows a plot of cell
yield as a function of time and clearly shows that the change in
necrosis correlates with the number of cells recovered from the
tumours. However, the effects on surviving fraction (described in
Figures 1-3) were not solely due to changes in cell yield, and this
is illustrated in Figure 6. The symbols in the Figure 6A show that
changes in toxicity of the drug combination as a function of time
after treatment is apparent when survival is measured as the
number of colonies counted divided by the number of cells plated
(i.e. no account is taken of effects on cell yield). RB6145 or nitro-
L-arginine alone killed no more than 20% ofcells when used alone.
However, when excision was within 2-4 h of the combined drug
treatment, there was a fourfold increase in cell killing, and this
became much greater when the time between treatment and exci-
sion was increased to 12 and 24 h. To gain some understanding of
B
Figure 4 H and E stained sections of an untreated KHT tumour (A) or a
tumour excised from a mouse 24 h after treatment with 300 mg kg-' RB 6145
plus 10 mg kg-' nitro-L-arginine (B)
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Figure 5 The effect on the number of cells recovered from KHT tumours in
mice given 300 mg kg-' RB6145 followed 15 min later by 10 mg kg-' nitro-L-
arginine vs the time after treatment when tumours are excised. The hatched
line is the yield of cells from untreated tumours or from those treated with
RB6145 or nitro-L-arginine only. Mean values are given ± se
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Figure 6 Absolute surviving fraction (i.e. colonies counted + cells plated) of
cells from KHT tumours treated with (A) RB6145 followed 15 min later by
10 mg kg-' nitro-L-arginine or (B) 1O-Gy local irradiation followed immediately
by 300 mg kg-1 RB6145. With dependence on time of tumour excision after
treatment. Mean values are given ± s.e. The hatched line is the survival of
tumour cells given 10 Gy only.
Table 2 Effect of RB6145 and nitro-L-arginine on CFU-A cells in KHT-
tumour-bearing mice
Treatment CFU-A cells per femur
Control 9.5x 103
300 mg kg-' RB6145 2.0 x 103
10 mg kg-' Nitro-L-arginine 8.6 x 103
RB6145 -* 15 min - nitro-L-arginine 1.6 x 103
the mechanism(s) underlying this temporal effect, experiments were
carried out in the absence of nitro-L-arginine to evaluate the time
course of the toxicity of RB6145 alone towards hypoxic tumour
cells. This was done by giving KHT tumours a single dose of 10-Gy
X-rays, administering RB6145 immediately after irradiation and
excising the tumours for determination of cell survival at various
times thereafter. This dose of radiation would sterilize the majority
of the aerobic cells in the KHT tumour, leaving the level of cell
survival to be governed by the residual radiation-resistant hypoxic
cells (Stratford et al, 1989). The symbols in Figure 6B show the
temporal dependence of the toxicity of RB6145 after irradiation. In
these radiation experiments, survival of tumour cells following 10-
Gy irradiation alone (hatched line) was independent oftime ofexci-
sion up to 24 h after treatment. Further, with or without RB6145,
there was no effect on cell yield; hence the data were plotted as
absolute surviving fraction, which allowed direct comparison with
the RB6145 plus nitro-L-arginine data (upper panel). Clearly, when
excision was at 2-4 h after treatment, there was a three- to fourfold
increase in cell killing of the residual radiation-resistant hypoxic
cells in the tumour. As the time to excision was increased to 12 and
24 h, there was further cell killing and, on theoretical grounds, this
20-fold increase over that seen with radiation alone was the
maximum achievable if all the hypoxic cells were sterilized
(Stratford et al, 1989). A similarity between Figure 6A and B is the
increase in cell killing that occurred in the 4- to 12-h period, and this
may be a reflection of the time that was necessary for RB6145 to
fully exert its cytotoxic action towards the hypoxic cells. This
suggests that nitro-L-arginine, by inducing further tumour hypoxia,
may have been amplifying the effects seen with RB6145 alone on
the small proportion of hypoxic cells that normally existed in the
KHT tumour. However, additional cell killing is observed for the
drug combination as the time between treatment and tumour exci-
sion is increased (12-24 h), which is not apparent in the irradiated
group. This, together with the large effect on cell yield in the drug
combination experiments (Figure 5), suggests that while RB6145-
mediated hypoxic cell toxicity is a common mechanism to both sets
ofexperiments, it is likely that additional mechanism(s) were opera-
tional when RB6145 was combined with nitro-L-arginine.
A final series of experiments were carried out to determine
whether the drug combination provides any potential therapeutic
benefit. In a previous study, Cole et al (1991) showed that
RB6145/RSU1069 could cause damage to bone marrow stem
cells. Survival ofCFU-A cells in tumour-bearing mice treated with
RB6145, nitro-L-arginine or the drug combination are summarized
in Table 2. As shown previously, RB6145 had a small but signifi-
cant effect on the number of viable bone marrow progenitor cells
recovered from femurs of C3H mice. However, the addition of
nitro-L-arginine showed no further toxicity. This contrasts with the
substantial anti-tumour effects that can be obtained with the drug
combination.
DISCUSSION
In this work, the original finding by Wood et al (1994) that an
inhibitor of NOS activity, nitro-L-arginine, can potentiate the
activity of the hypoxia-mediated bioreductive drug RB6145 has
been confirmed. It has been shown that the anti-tumour effects of
the drug combination occur in both the KHT sarcoma and the
SCCVII carcinoma. Evidence to suggest that this may be a more
general phenomena comes from the observation that nitro-L-
arginine potentiates RB6145 activity in the SaF tumour in CBA
mice (Horsman et al 1996).
The original hypothesis (Wood et al, 1993) was that inhibition of
NOS activity may compromise the vascular function of tumours,
leading to a decrease in tumour oxygenation that could enhance
bioreductive drug toxicity. Treatment of mice with nitro-L-arginine
results in a change in tumour redox status, as measured by 31P-MRS
and also an increase in tumour radiation resistance. Both these
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observations are consistent with an increase in tumour hypoxia
(Wood et al, 1993, 1994a and b). Meyer et al (1995) have demon-
strated that another inhibitor of NOS activity, monomethyl-
L-arginine decreased microvessel diameter, increased intermittent
flow and stasis and decreased red cell flow in a rat mammary
adenocarcinoma. Further, reductions in tumour blood flow of
about 50% after administration ofnitro-L-arginine have also been
measured in the rat DB9 tumour (Tozer et al, 1995) and in the
murine SaF tumour and C3H mammary carcinoma (Horsman et
al, 1996). However, in the later study, the blood flow changes
were not accompanied by significant changes in tumour pO2 as
measured by the Eppendorf histograph. In the SaF tumour under
ambient conditions, 70% of all pO2 readings were already less
than 2.5 mmHg (SA Hill, personal communication), hence a
transition to a more hypoxic state may not be very apparent in
this tumour using the Eppendorf method of measurement. Thus,
overall, it appears that the strategy of combining an inhibitor of
NOS activity with a hypoxia-mediated bioreductive drug
warrants further evaluation.
The effect ofthe drug combination is dependent on tumour size,
with larger KHT tumours being more sensitive. The hypoxic frac-
tion of murine tumours generally increases as a function of size,
and there is evidence to show that the hypoxic fraction of KHT
tumours increases with size in the range 6-12 mm in diameter
(Moulder et al, 1988). Although, in the present work, the increase
in sensitivity to RB6145/nitro-L-arginine as a function of tumour
size appeared to occur at the lower range of sizes reported by
Moulder et al (1988). Nevertheless it is likely that inhibition of
NOS activity, which would compromise the tone of vessels
feeding the tumour, would have a profound affect on the depth of
hypoxia in the larger tumours, and this would reflect itself in
response to RB6145 (Bremner, 1993).
RB6145 is completely converted to its active product RSU1069
within minutes of administration in vivo (Jenkins et al, 1990), and
the plasma half-life of RSU1069 is about 20 min in C3H mice
(Walton and Workman, 1988; Binger and Workman, 1990). It is
thought that RSU1069 would reach its maximum tumour concen-
tration within 15 min ofadministration, hence any interference with
tumour blood supply thereafter would not only create hypoxia but
also prevent efflux ofthe drug from the tumour, thereby enhancing
tumour toxicity (Bremner etal, 1990). The combination ofRB6145
and nitro-L-arginine was at its most potent when the drugs were
given within a short time of each other. However, substantial anti-
tumour effects were still seen when nitro-L-arginine was given
before the bioreductive drug, which suggests that the inhibition of
NOS does not significantly block tumour uptake of RB6145.
Horsman et al (1996) have shown that tumour blood flow changes
brought about by nitro-L-arginine lasted no more than an hour,
whereas the changes in redox status reported by Wood et al (1994a)
could last for up to 6 h. Thus, the underlying mechanism mediating
these anti-tumour effects is likely to be a complex interaction
between hypoxia induction and entrapment (distribution and phar-
macokinetics). Such interactions have been shown to contribute to
the potentiation ofthe activity ofboth RSU1069 and the alkylating
agent melphalan using a variety oftechniques for modifying blood
flow to tumours (Chaplin and Acker 1987; Stratford et al, 1988;
Bremner et al, 1990; Castellino et al, 1995).
A major contributory factor to the observed tumour cell kill is
the substantial effect on tumour cell yield. Similar effects in rodent
tumours have been seen in mice treated with flavone acetic acid
(FAA) and TNF-a (Edwards et al, 1991). However the tumour
necrosis caused by FAA is believed to be associated with elevated
production of nitric oxide as measured by elevation of plasma
nitrate levels (Veszelovsky et al, 1993), which is clearly the reverse
of that reported here. Haemorrhagic necrosis with the accompa-
nying effects on cell yield have also been seen after treatment with
tubulin-binding agents (Stephens and Peacock, 1978; Hill et al,
1994), but the mechanism is distinctly different to that for FAA
(Hill et al, 1995). Tumour experiments with bioreductive drugs
have not generally shown effects on cell yield. However, Brown et
al (1977, 1978) noted that mice treated with extremely high doses
ofthe nitroimidazole misonidazole showed an expansion oftumour
necrosis, and this was considered to be greater than that expected
on the basis of killing only the hypoxic cells in the tumour. In the
experiments described in this paper we have always used doses of
bioreductive drugs that alone or in combination are below their
maximum-tolerated doses (MTD) (Cole et al, 1991, 1992). In order
to test whether a phenomenon similar to that described by Brown
(1977) could be obtained with high doses (> MTD) of the potent
bifunctional nitroimidazoles used in this work, mice were given a
dose of 120 mg kg-' RSU1069 i.p. and tumour effects were
analysed 24 h later. This dose ofRSU1069 alone caused no clinical
signs ofwhole body toxicity over this time period, but a substantial
reduction (> 100-fold) in tumour cell yield was observed (Butler et
al, unpublished results). Therefore, as stated above, it may be that
the combination with nitro-L-arginine is simply amplifying the
mechanisms by which this bioreductive drug is active in these
tumours. Further, this effect appears to be tumour selective as nitro-
L-arginine caused no increase in normal tissue damage (as
measured by CFU-A survival) compared with RB6145/RSU1069
alone. Studies are currently underway to determine the mechanism
by which these hypoxia-medicated bioreductive drugs can cause
such a large loss of cells from tumours. Such knowledge could
allow these agents to be exploited more effectively.
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